Author: admin

Teleradiology Market worth $14.8 billion by 2026

“The size of global teleradiology market in terms of revenue was estimated to be worth $7.3 billion in 2021 and is poised to reach $14.8 billion by 2026, growing at a CAGR of 15.3% from 2021 to 2026”
Browse 142 market data Tables and 43 Figures spread through 225 Pages and in-depth TOC on “Teleradiology Market – Forecast to 2026

According to the new market research report “Teleradiology Market by Product & Service (Services, Hardware, Software (PACS, RIS)), Imaging Technique (MRI, CT, X-ray, Ultrasound, Mammography, Nuclear Imaging), End User (Hospitals, Diagnostic Centers & Laboratories), COVID-19 Impact – Forecast to 2026″, published by MarketsandMarkets™, the global market is expected to reach USD 14.8 billion by 2026 from USD 7.3 billion in 2021, at a CAGR of 15.3% during the forecast period of 2021 to 2026.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=8937290

Due to the outbreak of coronavirus globally, there is a sudden rise in the demand for teleradiology services. In 2021, teleradiology market reached to USD 7.3 billion. The growth of this market is mainly attributed to the rising geriatric population and the subsequent increase in the prevalence of associated diseases; the increasing number of advanced imaging procedures and a shortage of skilled radiologists; advancements in teleradiology the increasing adoption of cloud-based solutions. However, declining reimbursements and the increasing regulatory burden in the US are factors expected to restrain the market growth. Moreover, the increasing adoption of artificial intelligence and blockchain technology in teleradiology is expected to provide lucrative opportunities for the growth of the teleradiology market in the coming years.

Rise in the shortage of skilled radiologists to drive the demand for teleradiology.

Based on product and service, the market is segmented into teleradiology services, software, and hardware. The teleradiology services segment accounted for the largest share of 67.7% of the global teleradiology market in 2020. The large share of this segment can be attributed to the growing demand for faster and accurate diagnosis, shortage of skilled radiologists, and the growing number of COVID-19 cases worldwide.

The hospitals and clinics segment accounted for the largest market share in 2020

Based on end users, the teleradiology market is segmented into hospitals and clinics; diagnostic imaging centers and laboratories; long-term care centers, nursing homes, and assisted living facilities; and other end users. The hospitals and clinics segment accounted for the largest share in 2020. The large share of this segment can be attributed to the rising number of diagnostic imaging procedures performed in hospitals, the growing inclination of hospitals towards the automation and digitization of patient records, and the growing need to improve the quality of patient care. Diagnostic imaging centers and laboratories are expected to witness the highest growth during the forecast period, mainly due Factors such as the growing number of private imaging centers due to the rising demand for early diagnosis and a lack of imaging modalities in small and medium-scale hospitals.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=8937290

North America was the largest regional market for teleradiology market in 2020

The teleradiology market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latina America, and the Middle East and Africa. In 2020, North America accounted for the largest share. The large share of North America in the global market is attributed to the rising geriatric population, high incidence of chronic diseases, a large number of diagnostic imaging procedures, increasing awareness about the benefits of early diagnosis of diseases, and the rapid adoption of technologically advanced imaging systems in this region. Due to its growing geriatric population segment and environmental conditions have favored the spread of COVID-19 which has severely affected the region and ensured enormous growth in the demand for telehealth and teleradiology. Players in this and adjacent, or even non-related, markets have focused on or collaborated for expanding the services of teleradiology.

Some of the prominent players in this market are Cerner Corporation (US), Phillips Healthcare (Netherlands), Siemens Healthineers (Germany), McKesson Corporation (US), FUJIFILM Holdings Corporation (Japan), Agfa HealthCare (Belgium), Medica Group Plc. (UK), ONRAD, Inc. (US), RamSoft Inc. (Canada), NovaRad Corporation (US), TeleDiagnostic Solutions Pvt. Ltd. (India), 4ways Healthcare (UK), Teleradiology Solutions (India), TeleRad Tech (India), StatRad LLC (US), MedWeb LLC (US), WebRad TeleRadiology (India), Nautilus Medical (US), GE Healthcare (US), USARAD Holdings, Inc. (US), Everlight Radiology (Australia), and Mirada Medical (US).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=8937290

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.prnewswire.com/news-releases/teleradiology-market-worth-14-8-billion-by-2026–exclusive-report-by-marketsandmarkets-301460410.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Teleradiology Market worth $14.8 billion by 2026

Jeken Pest Control Company, Experts in Integrated Pest Management, Leads the Charge in Green Solutions for Sustainable Pest Management

Jeken’s integrated pest management solutions are leading the way in sustainable pest control. The company specializes in pheromone traps, insect-repellent products, and biological pest control.

Greater Taipei, Taoyuan, Hsinchu, Miasu, and Taichung area residents have a new choice when it comes to sustainably protecting their homes and businesses from pests: Jeken Pest Control Company. The leading green pest control expert is leading a revolution in pest control management with sustainable, safe, convenient, and budget-friendly solutions designed for modern consumers.

Chemical pesticides have long been the go-to quick solution for unwanted pests. However, as their effects on non-target species, including humans, persist, the toxicity of these methods has become a safety and environmental concern. At the same time, the growing invasion of new insecticide-resistant pests is leading homeowners to now demand pest-specific, safe, and sustainable pest control solutions.

With the demand for sustainable pest management practices increasing across the world, the pest control industry is undergoing a significant evolution. One of the key transformations is the ongoing transition to integrated pest management (IPM), a pest control approach that emphasizes prevention, monitoring and physical control measures. Hsu Hugo, a representative of Jeken Pest Control Company says this greener pest control approach has unleashed new realities within the industry. This has prompted pest control companies to rethink their methods.

As a leading green pest control expert, Jeken Pest Control Company has risen to the challenge. The pest control company offers cutting-edge pest control solutions through the integrated pest control and prevention method of IPM. Leveraging over ten years of industrial experience and an unparalleled commitment to delivering environmentally conscious solutions, Jeken has earned its reputation as the trusted partner for the best pest control solutions. The company is leading the charge in the use of pheromone traps, biological control methods, and eco-friendly insect repellent products. These approaches have proved effective in protecting homes and businesses from pest populations by controlling and preventing the spread of pest damage while reducing threats to human health and the environment.

In addition, Jeken’s IPM integrated pest management approach combines multiple control methods with accurate pest identification and monitoring to deliver customized solutions that reduce environmental disturbance and promote ecological balance. “Our goal is to create environments where our customers feel safe and at ease,” said Hugo. “Our blend of ecological control and regular monitoring brings our customers safe and sustainable solutions that drive advancements in forestry, agriculture and household pest management.”

Pest control isn’t just going green; it is also transitioning into a new era of digitalization. Jeken’s technical pest management services introduce the latest technologies and control strategies for early pest detection and timely intervention. Hugo explains that, like many pest control companies today, Jeken is continually developing innovative, environmentally friendly pest control solutions that align with evolving market demands and regulations. “We are firm believers that pest control should not be at the expense of the environment or human safety,” he said. “By introducing the latest technologies and control strategies for various pests, we are not only reducing the environmental impact of pest management but also actively contributing to pest control processes and systems that offer effective, long-term solutions.”

In this new era of pest control, Jeken Pest Control Company stands out as a powerhouse in pest control solutions that contribute to social development and improve environmental hygiene. The company’s range of pest management services, including detecting and purifying harmful substances in indoor air, sterilizing and disinfection, and its focus on safety and excellence, continue to set the standard for pest control services in Taiwan and beyond.

“Green pest management solutions may be a relatively new approach in pest control, but we are backed by ten years of knowledge and experience,” said Hugo. “We are excited to offer residents across cities in Taiwan access to new, safe, sustainable, affordable, and effective options when it comes to protecting their homes and businesses from mosquitoes, fleas, cockroaches, termites and other pests.”

Visit Jeken for customized, environmentally friendly pest control services that promise year-round protection.

About Jeken Pest Control Company:

Jeken Pest Control Company is passionate about finding and offering safer, more effective, and more sustainable pest solutions for residential and commercial clients. The company specializes in providing cutting-edge pest control solutions rooted in experience, past success, and an unwavering commitment to innovation.

Media Contact
Company Name: Jeken
Contact Person: Hsu Hugo
Email: Send Email
Country: Taiwan
Website: http://www.jeken.com.tw

Idiopathic Pulmonary Fibrosis Pipeline Drugs 2024 | FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharm

DelveInsight’s, “Idiopathic Pulmonary Fibrosis Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the Idiopathic Pulmonary Fibrosis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Idiopathic Pulmonary Fibrosis Pipeline Outlook

 

Key Takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report

  • August 2024:- Tvardi Therapeutics Incorporation- A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis. The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
  • August 2024:- GlaxoSmithKline- A Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study (TRANSFORM) to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF). Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participants.
  • DelveInsight’s Idiopathic Pulmonary Fibrosis pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Idiopathic Pulmonary Fibrosis treatment.
  • The leading Idiopathic Pulmonary Fibrosis Companies such as FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma Co., Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd., Ark Biosciences, Ocean Biomedical, and others.
  • Promising Idiopathic Pulmonary Fibrosis Therapies such as Pirfenidone, Deupirfenidone, SC1011, TTI-101, PLN-74809, GSK3915393, HZN-825, and others.

 

Stay ahead with the most recent pipeline outlook for Idiopathic Pulmonary Fibrosis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Idiopathic Pulmonary Fibrosis Treatment Drugs

 

Idiopathic Pulmonary Fibrosis Emerging Drugs

  • Pamrevlumab: FibroGen

Pamrevlumab is a proprietary therapeutic antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. Pamrevlumab represents a potential treatment for a broad array of fibrotic and proliferative disorders that affect organ systems throughout the body. Currently, the drug is in the Phase III stage of its development for the treatment of Idiopathic Pulmonary Fibrosis.

  • Tipelukast: MediciNova

MN-001 (tipelukast) is a novel, orally bioavailable small molecule compound which exerts its effects through several mechanisms to produce its anti-fibrotic and anti-inflammatory activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development and MN-001’s inhibitory effect on 5-LO and the 5-LO/LT pathway is considered to be a novel approach to treat fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. In addition, histopathological data shows that MN-001 reduces fibrosis in multiple animal models. The US Food and Drug Administration (FDA) has granted orphan-drug designation to MN-001 (tipelukast) for treatment of idiopathic pulmonary fibrosis (IPF). Currently, the drug is in the Phase II stage of its development for the treatment of IPF.

  • PLN-74809: Pliant Therapeutics

PLN-74809 is an oral small-molecule dual-selective inhibitor of αvβ6 and αvβ1 integrins for the treatment of IPF. While present at very low levels in healthy tissues, these integrins are upregulated in the lungs of IPF patients where they activate TGF-β, a key driver of the fibrotic process. Blocking these integrins is designed to stop TGF-β activation, potentially halting the growth of scar tissue. PLN-74809 has received Fast Track Designation and Orphan Drug Designation from the US Food and Drug Administration (FDA) in IPF and Orphan Drug Designation from the European Medicines Agency (EMA) in IPF. The company has completed enrollment in the Phase 2a clinical trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF) and announced positive data from the trial.

  • HZN-825: Horizon Pharmaceuticals

HZN-825 is an oral selective LPAR1 antagonist that has shown early signs of clinical impact in systemic sclerosis. LPAR1 signaling has been implicated in fibrosis and inflammation, and preclinical and clinical evidence support the antifibrotic potential of LPAR1 antagonism across multiple organ systems, including both lung and skin. Currently, the drug is in the Phase II stage of its development for the treatment of Idiopathic Pulmonary Fibrosis.

  • Brilaroxazine: Reviva Pharmaceuticals

Brilaroxazine, a novel serotonin-dopamine modulator with multifaceted activities has the potential to treat idiopathic pulmonary fibrosis (IPF). Serotonin (5-HT) signaling plays a key role, via 5-HT2A/2B/7 receptors, in the vasoactive effect on pulmonary arteries and lung myofibroblast actions. Brilaroxazine displays a high affinity and functional activity for the 5-HT2A/2B/7 receptors and moderate affinity for the serotonin transporter. Brilaroxazine’s effects on vascular fibrosis (5-HT2B receptor), proliferation (5-H2A/2B receptor), relaxation (5-HT2A receptor), inflammation (5-HT7 receptor), and pro-inflammatory cytokines have created interest in the potential to treat IPF. Brilaroxazine was evaluated in a bleomycin (BLM)-induced rat model of IPF receiving either brilaroxazine 15 mg twice daily for 21 days starting at day 1 (BT) or at day 10 (BI) and demonstrated efficacy with significant improvements in key endpoints in the bleomycin (BLM)-induced rat model of IPF. Currently, the drug is in the Phase I stage of its development for the treatment of IPF.

 

Explore groundbreaking therapies and clinical trials in the Idiopathic Pulmonary Fibrosis Pipeline. Access DelveInsight’s detailed report now! @ New Idiopathic Pulmonary Fibrosis Drugs

 

Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical

 

Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Unveil the future of Idiopathic Pulmonary Fibrosis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Idiopathic Pulmonary Fibrosis Market Drivers and Barriers

 

Scope of the Idiopathic Pulmonary Fibrosis Pipeline Report

  • Coverage- Global
  • Idiopathic Pulmonary Fibrosis Companies- FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma Co., Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd., Ark Biosciences, Ocean Biomedical, and others.
  • Idiopathic Pulmonary Fibrosis Therapies- Pirfenidone, Deupirfenidone, SC1011, TTI-101, PLN-74809, GSK3915393, HZN-825, and others.
  • Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Idiopathic Pulmonary Fibrosis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Idiopathic Pulmonary Fibrosis Companies, Key Products and Unmet Needs

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Idiopathic Pulmonary Fibrosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Idiopathic Pulmonary Fibrosis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Pamrevlumab: FibroGen
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Tipelukast: MediciNova
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Brilaroxazine: Reviva Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Idiopathic Pulmonary Fibrosis Key Companies
  21. Idiopathic Pulmonary Fibrosis Key Products
  22. Idiopathic Pulmonary Fibrosis- Unmet Needs
  23. Idiopathic Pulmonary Fibrosis- Market Drivers and Barriers
  24. Idiopathic Pulmonary Fibrosis- Future Perspectives and Conclusion
  25. Idiopathic Pulmonary Fibrosis Analyst Views
  26. Idiopathic Pulmonary Fibrosis Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Idiopathic Pulmonary Fibrosis Pipeline Drugs 2024 | FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharm

Lithium-ion Battery Recycling Market Growth Analysis, Opportunities, Leading Manufacturers, Share, Key Segmentation, Regional Analysis, and Forecast to 2032

“Browse 254 market data Tables and 50 Figures spread through 216 Pages and in-depth TOC on “Aerosol Cans Market””
The Lithium-ion Battery Recycling market is expanding due to rising EV adoption and environmental concerns. Key regions experiencing growth include North America and Europe, driven by stricter regulations and investments in advanced recycling technologies.

The global Lithium-ion battery recycling market is projected to grow from USD 16.2 billion in 2024 to USD 56.9 billion by 2032, at a CAGR of 17.0% during the forecast period. The rising consciousness among consumers about sustainability and environmental effects is a significant driver of the lithium-ion battery recycling market. The ecological footprint of products—including their lifecycle and end-of-life management—is becoming a more important consideration for consumers when making purchases. Manufacturers are being compelled to engage in ethical recycling methods as a result of consumers’ increased demand for items created from recycled materials. Prioritizing recycling can give businesses a competitive edge by appealing to environmentally conscious consumers, who are increasingly demanding openness in sourcing and production methods.    

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153488928  

Based on Source, the consumer electronics accounted segment for the largest share during the forecast period. Consumer electronics is projected to have the largest market share due to the shorter lifespans of batterie utilized in them when compared to energy storage systems and EVs.  In addition, this rise is supported by the growing use of lithium-ion batteries in laptops, cellphones, and other portable electronics. The significant volume of recyclable lithium-ion batteries produced by this industry is expected to aid the recycling sector as users refresh their devices on a regular basis.   

Based on Battery Chemistry, the lithium-iron phosphate segment accounted for the largest share,  of the overall Lithium-ion battery recycling market during the forecast period. This trend is being driven by the growing use of LFP batteries in electric vehicles because of its extended lifespan, affordability, and safety. The recycling sector will concentrate on recovering precious materials like lithium, iron, and phosphate as the quantity of end-of-life LFP batteries rises. The expansion of this market segment within the larger lithium-ion battery recycling market is also being aided by government policies and incentives that support battery recycling. 

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=153488928 

Based on region, Asia Pacific is the largest market for lithium-ion battery recycling, during the forecast period. There are a significant number of end-of-life batteries as a result of rapid industrialization, as well as an increase in the production of consumer electronics and electric vehicles. Infrastructure investments in recycling are also being driven by government programs that support resource recovery and sustainability. Furthermore, the area’s plentiful resources and labor force are reasonably priced, making it a desirable center for battery recycling businesses.

Major players operating in the Lithium-ion battery recycling market include Umicore (Belgium), Glencore (Switzerland), Cirba Solutions (US), Contemporary Amperex Technology Co., Ltd. (China), and RecycLiCo Battery Materials Inc. (Canada). The companies have wide-spread facilities with an established portfolio of lithium-ion battery recycling, a robust market presence, and strong business strategies. These factors are attributed to their progression in the lithium-ion battery recycling market.

Request Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=153488928

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/lithium-ion-battery-recycling-market-153488928.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lithium-ion Battery Recycling Market Growth Analysis, Opportunities, Leading Manufacturers, Share, Key Segmentation, Regional Analysis, and Forecast to 2032

Upcycled Food Products Market 2024: Emerging Trends, Growth Drivers, and Key Players

“Upcycled Food Products Market”
Upcycled Food Products Market is estimated to reach over USD 93.24 billion by 2031, exhibiting a CAGR of 6.53% during the forecast period.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Upcycled Food Products Market”-, By Type (Food and beverages, Personal Care Products, Household Products, Pet Food), By Source (Food waste, Agricultural By Products, Brewery and Distillery Waste), By Distribution Channel (Online, Offline), Industry Trends, and Global Forecasts, 2022-2035 And Segment Revenue and Forecast To 2031.”

The Upcycled Food Products Market is estimated to reach over USD 93.24 billion by 2031, exhibiting a CAGR of 6.53% during the forecast period. 

The term “upcycling” is commonly defined as reusing an object or material to create something of higher value or quality than the original. This process differs from recycling because it enhances the item’s value rather than breaking it down and remaking it. Upcycling is a key concept in the circular economy as it reduces waste and promotes the repurposing of previously used resources. Research in this field has explored a diverse range of upcycled foods, evaluating consumer acceptability of products made from olive, grain, meat, fruit, vegetable by-products, and even winemaking by-products. The growing cost of raw materials is expected to drive the size of the market for upcycled food items. The growing cost of raw materials is driving up the demand for recycled food products and forcing companies to look for alternative, less expensive sources of food ingredients. Businesses can cut expenses by repurposing excess or waste products that would otherwise go to waste through the process of upcycling food waste. This lessens the impact on the environment and fosters a more sustainable food system while also helping businesses boost their bottom line and cut their overall cost of production.

For Instance, in 2019, Turner Wyatt and Ben Gray, the founders of the Upcycled Food Association, recognized a need for a unified voice in the upcycled food industry. They connected with several firms producing upcycled foods but lacked consistent communication and representation, leading to the establishment of the UFA. Additionally, By September 2023, legislative support grew with the introduction of the bipartisan NO TIME TO Waste Act by Senators Coons (D-DE) and Moran (R-KS). This proposed Act includes funding for studies to evaluate the effects of the upcycled food industry and for a nationwide food waste reduction education program, which explicitly identifies repurposed food as a crucial solution.

Get Free Access to Demo Report, Excel Pivot and ToC : https://www.insightaceanalytic.com/request-sample/2638

List of Prominent Players in the Upcycled Food Products Market:

  • Blue Stripes LLC.
  • Outcast Foods
  • Abokichi
  • Alice & Ambre Inc
  • Diana’s Bananas, LLC
  • Superfrau
  • The Spare Food Co
  • Lost & Found Distillery Inc
  • Riff Cold Brewed
  • ReGrained
  • Toast Ale
  • RISE Products
  • Misfit Foods
  • US Foods
  • Agricycle Global
  • Pulp Pantry
  • SUPERFRAU
  • Blue Circle Foods
  • Riff
  • Barnana
  • Planetarians
  • ÄIO
  • Bake Me Healthy
  • Cascara Foods
  • Crust
  • Green Bowl,
  • I Am Grounded,
  • Matriark Foods
  • Oisix
  • Pluck
  • Rootly
  • RISE Products
  • Lost & Found Distillery Inc

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02

Market Dynamics:

Drivers:

Growing awareness of environmental issues and food waste is driving demand for sustainable and eco-friendly products. Consumers are more inclined to support upcycled food products that help reduce waste and promote sustainability. upcycled food products often offer nutritional benefits by repurposing high-value by-products that are rich in nutrients. This aligns with the growing trend of health-conscious eating. The food and Beverages segment includes a wide variety of products, from snacks and beverages to ingredients and ready-to-eat meals. This diversity allows for numerous upcycling opportunities.

Challenges:

Sourcing and processing upcycled materials can involve complex supply chains. Managing these effectively while ensuring consistent quality and safety is a significant challenge. Ensuring compliance with food safety standards and obtaining necessary certifications can be challenging for companies.

Regional Trends:

North America region leads in market share due to strong consumer awareness, high levels of innovation, and supportive regulatory frameworks. There is a growing demand for sustainable and eco-friendly products, driven by increasing environmental consciousness among consumers. Significant investment in upcycling technologies and innovation is seen, with many companies actively developing and marketing upcycled products. However, The Asia-Pacific region is seeing growing interest in upcycled food products, particularly in countries like Japan, South Korea, and Australia. Market growth is driven by increasing urbanization and rising awareness of food waste issues.

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/enquiry-before-buying/2638

Recent Developments:

  • In Nov 2023, Planetarians, a waste-to-food climate tech company, declared that it would bring its wholesome and reasonably priced meats to Expo City Dubai for COP28 UAE from November 30 to December 12 to demonstrate the possibility of producing sustainable proteins from recycled waste streams
  • In May 2023, ReGrained, launched a sourdough starter system with Puratos and a ReGrained partnership with supplies major Kerry to provide texture and nutrition to snack goods. Additionally, the company introduced baking mixes for brownies, carrot cake, banana bread, and pizza.

Segmentation of Upcycled Food Products Market.

Global Upcycled Food Products Market – By Type

  • Food and beverages
    • Food and beverages sub-type
      • Bakery and Snacks
      • Drinking Beverages
      • Dairy products
      • Personal Care Products
      • Household Products
      • Pet Food

Global Upcycled Food Products Market – By Source

  • Food waste
  • Agricultural by Products
  • Brewery and Distillery Waste

Global Upcycled Food Products Market – By Distribution Channel

  • Online
  • Offline

Global Upcycled Food Products Market – By Region

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2638

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Media Contact
Company Name: InsightAce Analytic Pvt. Ltd
Contact Person: Diana D’Souza
Email: Send Email
Country: United States
Website: https://www.insightaceanalytic.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Upcycled Food Products Market 2024: Emerging Trends, Growth Drivers, and Key Players

Temperature Controlled Pharmaceutical Packaging Solutions Market 2024: Trends, Innovations, and Key Players

“Temperature Controlled Pharmaceutical Packaging Solutions Market”
Temperature Controlled Pharmaceutical Packaging Solutions Market is estimated to reach over USD 8.64 billion by 2031, exhibiting a CAGR of 6.7% during the forecast period.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Temperature Controlled Pharmaceutical Packaging Solutions Market”- By Product Type (Insulated Shippers (Panels & Envelopes, EPS Foam Containers, Fibreboard, PUR Containers) Insulated Protective Shippers, Insulated Containers (Chest Style, Upright Style, Others)), By Application (Frozen, Chilled, Ambient) Industry Trends, and Global Forecasts, 2022-2035 And Segment Revenue and Forecast To 2031.”

The Temperature Controlled Pharmaceutical Packaging Solutions Market is estimated to reach over USD 8.64 billion by 2031, exhibiting a CAGR of 6.7% during the forecast period. 

The creation of temperature-sensitive pharmaceuticals, including biologics, vaccines, and specialty treatments, has increased significantly in the pharmaceutical sector worldwide. Strict temperature control must be maintained at all times throughout the supply chain in order to protect these goods’ effectiveness and safety. Pharmaceutical businesses are therefore actively looking for packaging options that can precisely maintain temperature ranges throughout storage and transit. The pharmaceutical packaging market that is temperature-controlled comprises a wide range of items, such as thermal packaging accessories, phase change materials, temperature monitoring devices, and insulated shipping containers. The purpose of these solutions is to guarantee the integrity and potency of pharmaceutical products during their transportation from manufacturing facilities to end users by offering efficient thermal insulation, continuous temperature monitoring, and protection against temperature fluctuations.

The growing use of highly temperature-sensitive biologics and customized medications is one of the main factors propelling this market. For biologics to remain stable and effective, such as vaccinations and protein-based medicines, temperature regulation must be strictly adhered to. The need for temperature-controlled pharmaceutical packaging solutions is being driven by the rising incidence of chronic illnesses and the desire for individualized therapies.

Get Free Access to Demo Report, Excel Pivot and ToC : https://www.insightaceanalytic.com/request-sample/2594

List of Prominent Players in the Temperature Controlled Pharmaceutical Packaging Solutions Market:

  • Sonoco Products Company
  • Pelican Biothermal
  • Sofrigam SA Ltd.
  • Cryopak
  • Cold Chain Technologies
  • Envirotainer Ltd.
  • Cencora Inc.
  • Inmark Packaging
  • American Aerogel Corporation
  • Aeris Dynamics

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02

Market Dynamics:

Drivers:

The increasing use of biologics and specialty drugs, which are highly sensitive to temperature variations, drives the need for advanced packaging solutions. Expansion in these sectors, particularly with the development of new drugs and vaccines, further boosts the demand for temperature-controlled packaging. The growing complexity of global supply chains and the necessity for efficient cold chain logistics to transport temperature-sensitive products across various climates and geographies also contribute to this demand. Strict regulations on product quality and safety necessitate reliable temperature control to ensure pharmaceutical products remain effective and safe during storage and transportation. Additionally, the increasing focus on sustainability drives the adoption of biodegradable and eco-friendly materials in temperature-controlled packaging solutions.

Challenges:

Advanced temperature-controlled packaging solutions and technologies can be expensive, making it challenging for some companies to adopt them, especially smaller pharmaceutical firms. The global nature of pharmaceutical supply chains makes them vulnerable to disruptions, such as natural disasters, political instability, or pandemics, which can impact the availability and effectiveness of temperature-controlled logistics.

Regional Trends:

North America has the largest market share due to advanced healthcare infrastructure well-established pharmaceutical industries and extensive networks of healthcare providers. This infrastructure supports the demand for temperature-sensitive medications, vaccines, and biologics, driving the need for a robust packaging solution. The region has a strong focus on biopharmaceuticals, which are often more sensitive to temperature fluctuations compared to traditional chemical-based drugs. Meanwhile, the Asia-Pacific area is seeing significant expansion due to factors such as increased healthcare spending, growing e-commerce, and growing pharmaceutical production capabilities, which are creating a demand for dependable cold-chain solutions.

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/enquiry-before-buying/2594

Recent Developments:

  • In Aug 2023, Sonoco added two additional cold seal structures to the expanding line of EnviroFlex® Paper products that have been pre-qualified for wide recycling by How2Recycle®. The EnviroFlex Paper Ultimate (ULT) 1.0 CS and Advanced (ADV) 4.0 CS are the pioneer products in curbside recyclable paper packaging that offer cold seal qualities. This is the outcome of Sonoco’s continuous efforts to create and offer a variety of creative and environmentally friendly packaging options to satisfy the demanding requirements of consumer-packaged goods manufacturers in the cutthroat industry.
  • In April 2023, Sonoco declared that EnviroFlex® Paper Ultimate (ULT) 1.0, a high-barrier paper-based structure, has been pre-qualified by How2Recycle and has fulfilled all the requirements of the Fibre Box Association’s Voluntary Standard for Repulping and Recycling.

Segmentation of Temperature Controlled Pharmaceutical Packaging Solutions Market.

Global Temperature Controlled Pharmaceutical Packaging Solutions Market, By Product Type,

  • Insulated Shippers
    • Panels & Envelopes
    • EPS Foam Containers
    • Fibreboard
    • PUR Containers
    • Insulated Protective Shipper
    • Insulated Containers
      • Chest Style
      • Upright Style
      • Others

Global Temperature Controlled Pharmaceutical Packaging Solutions Market – By Application

  • Frozen
  • Chilled
  • Ambient

Global Temperature Controlled Pharmaceutical Packaging Solutions Market – By Region

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2594

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Media Contact
Company Name: InsightAce Analytic Pvt. Ltd
Contact Person: Diana D’Souza
Email: Send Email
Country: United States
Website: https://www.insightaceanalytic.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Temperature Controlled Pharmaceutical Packaging Solutions Market 2024: Trends, Innovations, and Key Players

Paints & Coatings Market Trends, Opportunities, Graph, Key Segmentation, Regional Growth, Leading Companies, and Forecast to 2029

“Browse 456 market data Tables and 62 Figures spread through 410 Pages and in-depth TOC on “Paints & Coatings Market””
The Paints & Coatings market, driven by the construction, automotive, and industrial sectors, is growing due to rising demand for durable, protective, and decorative coatings. Innovations focus on sustainability, including low-VOC and eco-friendly products.

The paints & coatings market is projected to grow from USD 194.5 billion in 2024 to USD 227.5 billion by 2029, at a CAGR of 3.2% between 2024 and 2029. Globally, the paint and coatings market has grown at a moderate rate, and this trend is anticipated to continue. The automobile OEMs, construction, refinishing, and architectural sectors are the main drivers of the market. Globally, China and India are at the top of the paint and coatings market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=156661838  

The major markets are in Asia Pacific, followed by North America and Europe. The Asia Pacific region’s growth is mostly attributable to strong economic growth and significant investments made in a range of industries, including general industrial, construction, automobile OEMs, and architecture. The manufacturing sector has benefited greatly from the global economic recovery, while the demand for new residential development and infrastructure has been fueled by rising urbanization.

The construction and renovation of roads, bridges, water and sewer systems, smart cities, and other infrastructure have increased demand for paints and coatings. In contrast, industrialized economies such as the US, Germany, UK, France, and Japan have matured markets for paints & coatings. As a result, in order to combat concerns such as declining sales, many businesses are refocusing their efforts in areas with consistent demand.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=156661838 

Economic uncertainty, erratic raw material costs, unstable foreign exchange rates, sluggish economic growth, and the disparity between raw material supply and demand are the main obstacles faced by producers of paints & coatings in developed nations. In order to maintain their competitive edge and take advantage of the rising demand for paints and coatings worldwide, these factors have forced manufacturers to investigate new strategies, such as diversifying their product portfolios, investing in research and development, and increasing their presence in emerging markets.

The major players operating in this business include Akzo Nobel N.V. (Netherlands), PPG Industries Inc. (US), The Sherwin-Williams Company (US), Axalta Coating Systems LLC. (US), Jotun A/S (Norway) and others.

Inquire Now: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=156661838 

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/paint-coating-market-156661838.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Paints & Coatings Market Trends, Opportunities, Graph, Key Segmentation, Regional Growth, Leading Companies, and Forecast to 2029

A Glimpse into the Life of a Master by Chelsea Velinov

An extraordinary photograph of Pablo Picasso has surfaced, offering a rare glimpse into the daily life of one of the 20th century’s most influential artists. The black-and-white image captures Picasso in his studio, surrounded by the tools and works-in-progress that defined his creative space.

In the photograph, Picasso is seen standing next to a unique, cylindrical heating stove, dressed casually in a loose-fitting coat and flat cap, his expression focused yet enigmatic. The studio is a cluttered sanctuary filled with artistic paraphernalia — paintings, sculptures, and various objects that hint at the eclecticism of his interests and inspirations.

Behind Picasso, a partially obscured portrait painting suggests the presence of another of his masterpieces, likely still in the process of creation. The studio’s ambiance, reflected in the disarray of the objects and the concentration of the artist, speaks volumes about Picasso’s relentless pursuit of artistic innovation.

This image is more than just a photograph; it is a window into the mind of a genius. Picasso’s studio was a place where conventional boundaries were challenged, and the very definition of art was reimagined. The photo captures the artist during what appears to be a moment of quiet contemplation, perhaps planning his next bold stroke or innovative sculpture.

The photograph also highlights the stark contrast between Picasso’s simple attire and the grandeur of his artistic legacy. It is a reminder that despite his fame and success, Picasso remained deeply connected to the simplicity of his craft.

This image of Picasso in his element will undoubtedly captivate art enthusiasts and historians alike, offering them a deeper understanding of the man behind the masterpieces. It serves as a powerful reminder of Picasso’s enduring influence on the world of art and the timeless nature of his work.

Note: The content has been provided by Chelsea Velinov.

Media Contact
Company Name: ArtDependence
Contact Person: Vilnov
Email: Send Email
City: Antwerpen
State: Brussels
Country: Belgium
Website: www.artdependence.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: A Glimpse into the Life of a Master by Chelsea Velinov

Non-muscle Invasive Bladder Cancer Pipeline Drugs 2024 | Prokarium Ltd, Vaxiion Therapeutics, Tyra Biosciences, Lipac Oncology, SURGE Therapeutics, Jiangsu Simcere Pharmaceutical, Shanghai Hengrui Pha

DelveInsight’s, “Non Muscle Invasive Bladder Cancer Pipeline Insight 2024” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the Non-muscle Invasive Bladder Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Non-muscle Invasive Bladder Cancer Pipeline Outlook

 

Key Takeaways from the Non-muscle Invasive Bladder Cancer Pipeline Report

  • August 2024:- Janssen Research & Development LLC- A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator’s Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy. The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator’s choice of single agent intravesical chemotherapy.
  • August 2024:- Protara Therapeutics- A Phase 2, Open-Label Study to Evaluate the Safety and Anti-Tumor Activity of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer. TARA-002-101-Ph2 is an open-label study to investigate the safety and anti-tumor activity of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1).
  • DelveInsight’s Non-muscle Invasive Bladder Cancer pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Non-muscle Invasive Bladder Cancer treatment.
  • The leading Non-muscle Invasive Bladder Cancer Companies such as Prokarium Ltd, Vaxiion Therapeutics, Tyra Biosciences, Lipac Oncology, SURGE Therapeutics, Jiangsu Simcere Pharmaceutical, Shanghai Hengrui Pharmaceutical Co., enGene, and others.
  • Promising Non-muscle Invasive Bladder Cancer Therapies such as TAR-200, Mitomycin C, Gemcitabine, Avelumab, RC48-ADC, and others.

 

Stay ahead with the most recent pipeline outlook for Non-muscle Invasive Bladder Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Non-muscle Invasive Bladder Cancer Treatment Drugs

 

Non Muscle Invasive Bladder Cancer Emerging Drugs

  • TAR-200: TARIS Biomedical

TAR-200 is an investigational targeted releasing system enabling controlled release of gemcitabine into the bladder, sustaining local drug exposure for weeks at a time. The safety and efficacy of TAR-200 are being evaluated in Phase II and Phase III studies in patients with muscle-invasive bladder cancer in SunRISe-2 and SunRISe-4 and NMIBC in SunRISe-1 and SunRISe-3. Currently, the drug is in Phase III stage of its clinical trial for the treatment of non muscle invasive bladder cancer.

  • VAX 014: Vaxiion Therapeutics

VAX014 is a novel rBMC-based oncolytic immunotherapy designed to have distinct advantages over traditional and emerging oncolytic virotherapies. VAX014’s ability to specifically target both alpha3beta1(α3β1) and alpha5beta1 (α5β1) integrins facilitates broad spectrum activity against various solid tumor types because these two integrin family members are clinically validated as being selectively expressed or overexpressed in a wide variety of solid tumor indications (and most mouse models). Currently, the drug is in the Phase I stage of its development for the treatment of Non muscle-invasive bladder cancer.

  • SIM0237: Simcere Pharmaceutical Group

SIM0237 is an anti-PD-L1 monoclonal antibody fused with potency-reduced IL-15/IL-15Rα sushi domain developed in-house by utilizing Simcere Zaiming’s protein engineering platform. As a bifunctional protein, the compound can block the PD-1/PD-L1 immunosuppressive pathway via binding to PD-L1 and activate the immune system through its IL-15 part, thus playing a synergistic role of relieving immunosuppression and boosting the immune activation to exhibit antitumor effect. The attenuated IL-15 part of SIM0237 increases MTD and avoids overstimulation and accompanied anergy of NK and CD8+ T cells. In the meantime, fusion of attenuated IL-15 to full anti-PD-L1 mAb further enhances the half-life of attenuated IL-15 and delivers IL-15 directly to the tumor microenvironment avoiding notorious CRS toxicity induced by systemic IL-15 exposure. Currently, the drug is in Phase I stage of its clinical trial for the treatment of non muscle invasive bladder cancer.

 

Explore groundbreaking therapies and clinical trials in the Non-muscle Invasive Bladder Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Non-muscle Invasive Bladder Cancer Drugs

 

Non Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Non-muscle Invasive Bladder Cancer Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Unveil the future of Non-muscle Invasive Bladder Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Non-muscle Invasive Bladder Cancer Market Drivers and Barriers

 

Scope of the Non-muscle Invasive Bladder Cancer Pipeline Report

  • Coverage- Global
  • Non-muscle Invasive Bladder Cancer Companies- Prokarium Ltd, Vaxiion Therapeutics, Tyra Biosciences, Lipac Oncology, SURGE Therapeutics, Jiangsu Simcere Pharmaceutical, Shanghai Hengrui Pharmaceutical Co., enGene, and others.
  • Non-muscle Invasive Bladder Cancer Therapies- TAR-200, Mitomycin C, Gemcitabine, Avelumab, RC48-ADC, and others.
  • Non-muscle Invasive Bladder Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Non-muscle Invasive Bladder Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Non-muscle Invasive Bladder Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Non-muscle Invasive Bladder Cancer Companies, Key Products and Unmet Needs

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Non Muscle Invasive Bladder Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Non Muscle Invasive Bladder Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. TAR-200: TARIS Biomedical
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Drug name: Company name
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. VAX 014: Vaxiion Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Non Muscle Invasive Bladder Cancer Key Companies
  21. Non Muscle Invasive Bladder Cancer Key Products
  22. Non Muscle Invasive Bladder Cancer- Unmet Needs
  23. Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
  24. Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
  25. Non Muscle Invasive Bladder Cancer Analyst Views
  26. Non Muscle Invasive Bladder Cancer Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-muscle Invasive Bladder Cancer Pipeline Drugs 2024 | Prokarium Ltd, Vaxiion Therapeutics, Tyra Biosciences, Lipac Oncology, SURGE Therapeutics, Jiangsu Simcere Pharmaceutical, Shanghai Hengrui Pha

Frank Flora, Jupiter Entrepreneur, is Revving Up The Automotive Scene With His Autobody Shop

Frank Flora, Jupiter Entrepreneur, is Revving Up The Automotive Scene With His Autobody Shop

Frank Flora of Jupiter, FL

Jupiter, FL – Frank Flora, a dynamic entrepreneur and well-known figure in Jupiter, is making waves in the local automotive industry with the grand opening of his state-of-the-art autobody shop. This new venture marks Flora’s latest contribution to the community, bringing advanced automotive repair and customization services to the heart of Jupiter.

Cutting-Edge Autobody Services by Frank Flora in Jupiter

The autobody shop is not just another repair facility; it’s a cutting-edge establishment equipped with the latest technology and staffed by highly skilled technicians. Frank Flora’s vision is to provide exceptional service, ensuring every vehicle is treated with the utmost care and precision. Whether a minor dent repair or a complete vehicle overhaul, Flora’s team is ready to deliver top-tier results.

Frank Flora’s Commitment to Excellence in Jupiter’s Automotive Scene

“I’ve always had a passion for cars and a deep commitment to serving my community,” said Frank Flora. “With this autobody shop, I’m combining both by offering a service that’s necessary and delivered with excellence. I’m excited to contribute to Jupiter’s thriving business scene and to help keep our community’s vehicles in prime condition.”

Specialization and Customization: Frank Flora’s Autobody Shop in Jupiter

In addition to standard autobody services, the shop offers specialized customization options, catering to car enthusiasts looking to personalize their vehicles. From unique paint jobs to performance enhancements, Flora’s shop is set to become Jupiter’s go-to destination for automotive enthusiasts.

Why Choose Frank Flora’s Autobody Shop in Jupiter?

Frank Flora of Jupiter, FL, autobody shop is already gaining attention for its customer-centric approach, where every client is treated like family. The shop’s welcoming atmosphere and cutting-edge capabilities are expected to set a new standard in the local automotive repair industry.

Visit Frank Flora’s Autobody Shop in Jupiter Today

Located conveniently in Jupiter, the autobody shop is now open for business and ready to serve the community. For more information or to schedule an appointment, contact us today!

About Frank Flora: Jupiter’s Visionary Entrepreneur

Frank Flora is a seasoned entrepreneur with a strong background in various business ventures. Known for his innovative approach and dedication to quality, Flora has established himself as a key player in Jupiter’s business community. His latest endeavor, the autobody shop, is a testament to his commitment to excellence and passion for the automotive industry.

Media Contact
Company Name: Frank Flora Auto Body Shop Jupiter
Contact Person: Frank Flora
Email: Send Email
Phone: (561) 123-4567
Address:123 Jupiter St
City: Jupiter
State: Florida
Country: United States
Website: https://finance.yahoo.com/news/frank-flora-jupiter-fl-opens-130000526.html